Global In Vitro Fertilization (IVF) Market Size, Share, Opportunities, And Trends By Cycle Type (Fresh IVF Cycle, Thawed IVF Cycle, Donor Egg IVF Cycles), By End User (Fertility Clinics, Hospitals And Research Centers), And By Geography - Forecasts From 2024 To 2029

The global In Vitro Fertilization (IVF) market is anticipated to grow at a compound annual growth rate (CAGR) of 9.37% over the forecast period to reach US$45.895 billion by 2029, increasing from US$24.520 billion in 2022.

The growing prevalence of male infertility, rising median age of first-time mothers, rising obesity, falling fertility rates, and rising alcohol consumption are the main factors propelling the global in-vitro fertilization market. Furthermore, the need for in-vitro fertilization is being driven by the growing awareness of infertility and the accessibility of cutting-edge treatment options. One important factor driving growth is the increasing median age of first-time mothers.

Moreover, the growing human population has resulted in a significant increase in the median age of first-time mothers, as more women are prioritizing their careers over family planning and later marriages than in the past. The median age of first-time mothers has also been greatly impacted by the effective use of contraceptives, and this is expected to have a major positive impact on the growth of the in vitro fertilization (IVF) market growth. Further, infertility affects a significant portion of the population at some point in their lives, according to a WHO report. Approximately 1 in 6 adults globally, or 17.5% of the population, are infertile, demonstrating the critical need to expand access to high-quality, reasonably priced reproductive care for those who require it 

Moreover, the growing human population has resulted in a significant increase in the median age of first-time mothers, as more women are prioritizing their careers over family planning and later marriages than in the past. The median age of first-time mothers has also been greatly impacted by the effective use of contraceptives, and this is expected to have a major positive impact on the growth of the in vitro fertilization (IVF) market growth. Further, infertility affects a significant portion of the population at some point in their lives, according to a WHO report. Approximately 1 in 6 adults globally, or 17.5% of the population, are infertile, demonstrating the critical need to expand access to high-quality, reasonably priced reproductive care for those who require it 

The rising popularity of sperm separation systems

Sperm separation systems are used in the majority of assisted reproductive technologies (ART), including artificial insemination and in vitro fertilization (IVF). Since these systems provide purified samples that can be used in subsequent procedures, they are essential to assisted reproductive technologies (ARTs). These systems are essential to ARTs because they supply refined samples for additional processing. The market is expanding due in part to companies' increased focus on creating innovative devices that can be used in assisted reproductive technology (ART) procedures carried out by fertility clinics and obstetrician-gynecologist (OB/GYN) practices.

Moreover, compared to intracytoplasmic sperm injection, sperm syringes offer clinics a promising alternative for implementing less invasive assisted reproductive technologies (ARTs), thereby minimizing the associated clinical strain and improving the long-term health outcomes for ART-conceived children.

Additionally, the market is growing as a result of the increasing technological developments in the sperm separation market. For instance, in March 2022, Malta began research and development of an AI-powered sperm and egg selection technology for fertility treatments in partnership with Pera Labs's commercialization advisors at the University City Science Center. Together with Pera Labs's funding, Malta Enterprise's EUR 800,000 financial support speeds up the company's operations in Malta.  These R&D programs and investments have impacted the market in a positive way which has increased the birth rate. For instance, as per the Australian Institute of Health and Welfare, the number of births given by women increased from 2,91,712 in 2020 to 3,11,360 in 2021.

The fertility clinics segment of the global IVF market

IVF is widely used in fertility clinics. IVF is a form of assisted reproductive technology. (ART). IVF is a process of extracting a woman’s eggs, fertilizing them in a lab, and transferring the output into the uterus through the cervix.

Approximately 238,126 individuals underwent 413,776 ART cycles at 453 reporting clinics in the United States in 2021, according to the CDC's 2021 Fertility Clinic Success Rates Report. This resulted in 91,906 live births (deliveries of one or more living children) and 97,128 live-born infants. 167,689 of the 413,776 ART cycles carried out in 2021 involved egg or embryo banking cycles, in which all of the produced eggs or embryos were saved for later use. Over the past ten years, the usage of ART has more than doubled, although it is still comparatively uncommon when compared to the potential demand. Every year, 2.3% of all babies born in the US are created with the use of assisted reproductive technology .

IVF is growing at a great pace due to the rising problem of infertility amongst the younger generations. Millions of Americans struggle with infertility, a problem that can have a significant negative impact on one's well-being. A recent National Survey of Family Growth estimated that 9% of married women between the ages of 15 and 49 are thought to be infertile in one way or another. An earlier iteration of the poll calculated that 9% of men between the ages of 15 and 44 are infertile in one way or another. An estimated 1 in 8 women between the ages of 15 and 49 have sought infertility services at some point in their lives due to difficulties conceiving. Not only can same-sex couples and single people who want a child seek fertility aid, but so can those facing infertility issues .

Mergers and acquisitions across different companies further drive the market towards growth. Life Whisperer and ESHRE began their third international IVF clinic collaboration in June 2021 to apply artificial intelligence to oocytes. The goal of the AI Open Project was to use AI to evaluate oocytes, or female eggs, before fertilization or freezing.  Additionally, the largest fertility chain in India, Nova IVF Fertility, owned by Asia Healthcare Holdings, said in January 2021 that it was expanding its network in the National Capital Region (NCR) by forming a strategic alliance with Southend Fertility & IVF, a prominent provider of IVF services in Delhi NCR.

The market is projected to grow in the North American region.

Various factors are contributing to the in vitro fertilization industry's explosive growth in the United States. For instance, couples are experiencing an increase in infertility problems, mostly as a result of changing lifestyles and delaying having children. Moreover, the success rates of in vitro fertilization are increasing due to advances in reproductive technologies, such as preimplantation genetic testing and embryo cryopreservation, overall boosting the industry's growth.

In vitro fertilization (IVF) and other assisted reproductive technology (ART) operations provide infertile individuals with a possible means of growing their families. IVF is a crucial fertility therapy option that helps people conceive who would not be able to use other treatments. It accounts for more than 99% of ART operations performed. 86,146 babies, or 2.3% of all babies born in the United States in 2021, were conceived with the use of assisted reproductive technology.

Some other factors driving market development are cultural acceptance of nontraditional family-building alternatives and the growing trend of medical tourism. Overall, these highlight the US's status as a leading center for in vitro fertilization services, propelling the sector's continuous expansion.

Various product innovation strategies by key market players are further fuelling the market. For instance, Leading fertility technology company Alife Health ("Alife"), which specializes in creating artificial intelligence (AI) tools for in vitro fertilization (IVF), has announced a ground-breaking collaboration with Boston IVF, a prominent fertility clinic with over 25 locations nationwide, to test the nation's first AI tool for optimizing IVF medication.  Moreover, in October 2023, the largest provider of comprehensive fertility products and services in North America, Inception FertilityTM (Inception), announced its participation at the 2023 ASRM Scientific Congress, which was held in New Orleans, Louisiana, from October 14-18, 2023. This announcement demonstrated Inception's continued commitment to advancing the field of reproductive medicine.

Furthermore, the cost of one IVF cycle might reach as much as $30,000, with estimates ranging from $15,000 to $20,000.9. Since it typically takes 2.5 cycles to conceive with IVF, the average cost of the procedure to conceive successfully can easily surpass $40,000.10, 11, and 12. According to a study conducted among Californian reproductive clinics, the average out-of-pocket expenses for IVF cycles were $24,000 ($61,000 for each successful outcome) and $38,000 for cycles using donor eggs ($73,000 for each successful outcome). 

Key Market Developments:

• January 2023,

Key Players:

• Leading the way in new technologies and services for each stage of the ART process is CooperSurgical Fertility Solutions, a global pioneer in reproductive genetics and IVF.
• Vitrolife is a firm that provides in vitro fertilization (IVF). Our solutions are designed to maximize efficiency in every treatment and to improve therapeutic results. Building a dependable standardized technique on a broad variety of interoperable components makes the process considerably simpler.
• Nunc in vitro fertilization (IVF) products from Thermo Scientific are manufactured following ISO 13485 standards and have a CE marking for IVD devices. Through the company’s thorough quality control methods, including MEA and HSSA release testing, Nunc IVF solutions exceed strict quality criteria, helping to assure reliability for all of customers’ IVF demands

Segmentation:

• By Cycle Type:
  • Fresh IVF Cycle
  • Thawed IVF Cycle
  • Donor Egg IVF Cycle
• By End-User
  • Fertility Clinics
  • Hospitals and Research Centers
• By Geography
  • North America
    • USA
    • Canada              
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Thailand
    • Indonesia
    • Others

---

1. INTRODUCTION

1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base and Forecast Years Timeline

1.8. Key Benefits for the Stakeholders

2. RESEARCH METHODOLOGY

2.1. Research Design

2.2. Research Process

3. EXECUTIVE SUMMARY

3.1. Key Findings

3.2. Analyst View

4. MARKET DYNAMICS

4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Forces Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis

4.5. Analyst View

5. GLOBAL IN VITRO FERTILIZATION (IVF) MARKET BY CYCLE TYPE

5.1. Introduction 

5.2. Fresh IVF Cycle

5.2.1. Market Trends and Opportunities

5.2.2. Growth Prospects

5.2.3. Geographic Lucrativeness

5.3. Thawed IVF Cycle

5.3.1. Market Trends and Opportunities

5.3.2. Growth Prospects

5.3.3. Geographic Lucrativeness

5.4. Donor Egg IVF Cycle

5.4.1. Market Trends and Opportunities

5.4.2. Growth Prospects

5.4.3. Geographic Lucrativeness

6. GLOBAL IN VITRO FERTILIZATION (IVF) MARKET BY END-USER

6.1. Introduction 

6.2. Fertility Clinics

6.2.1. Market Trends and Opportunities

6.2.2. Growth Prospects

6.2.3. Geographic Lucrativeness

6.3. Hospitals and Research Centers

6.3.1. Market Trends and Opportunities

6.3.2. Growth Prospects

6.3.3. Geographic Lucrativeness

7. GLOBAL IN VITRO FERTILIZATION (IVF) MARKET BY GEOGRAPHY

7.1. Introduction

7.2. North America

7.2.1. By Cycle Type

7.2.2. By End-User

7.2.3. By Country

7.2.3.1. USA

7.2.3.1.1. Market Trends and Opportunities

7.2.3.1.2. Growth Prospects

7.2.3.2. Canada

7.2.3.2.1. Market Trends and Opportunities

7.2.3.2.2. Growth Prospects

7.2.3.3. Mexico

7.2.3.3.1. Market Trends and Opportunities

7.2.3.3.2. Growth Prospects

7.3. South America

7.3.1. By Cycle Type

7.3.2. By End-User

7.3.3. By Country

7.3.3.1. Brazil

7.3.3.1.1. Market Trends and Opportunities

7.3.3.1.2. Growth Prospects

7.3.3.2. Argentina

7.3.3.2.1. Market Trends and Opportunities

7.3.3.2.2. Growth Prospects

7.3.3.3. Others

7.3.3.3.1. Market Trends and Opportunities

7.3.3.3.2. Growth Prospects

7.4. Europe

7.4.1. By Cycle Type

7.4.2. By End-User

7.4.3. By Country

7.4.3.1. Germany

7.4.3.1.1. Market Trends and Opportunities

7.4.3.1.2. Growth Prospects

7.4.3.2. France

7.4.3.2.1. Market Trends and Opportunities

7.4.3.2.2. Growth Prospects

7.4.3.3. United Kingdom

7.4.3.3.1. Market Trends and Opportunities

7.4.3.3.2. Growth Prospects

7.4.3.4. Italy

7.4.3.4.1. Market Trends and Opportunities

7.4.3.4.2. Growth Prospects

7.4.3.5. Others

7.4.3.5.1. Market Trends and Opportunities

7.4.3.5.2. Growth Prospects

7.5. Middle East and Africa

7.5.1. By Cycle Type

7.5.2. By End-User

7.5.3. By Country

7.5.3.1. Saudi Arabia

7.5.3.1.1. Market Trends and Opportunities

7.5.3.1.2. Growth Prospects

7.5.3.2. UAE

7.5.3.2.1. Market Trends and Opportunities

7.5.3.2.2. Growth Prospects

7.5.3.3. Others

7.5.3.3.1. Market Trends and Opportunities

7.5.3.3.2. Growth Prospects

7.6. Asia Pacific

7.6.1. By Cycle Type

7.6.2. By End-User

7.6.3. By Country

7.6.3.1. India

7.6.3.1.1. Market Trends and Opportunities

7.6.3.1.2. Growth Prospects

7.6.3.2. China

7.6.3.2.1. Market Trends and Opportunities

7.6.3.2.2. Growth Prospects

7.6.3.3. Japan

7.6.3.3.1. Market Trends and Opportunities

7.6.3.3.2. Growth Prospects

7.6.3.4. South Korea

7.6.3.4.1. Market Trends and Opportunities

7.6.3.4.2. Growth Prospects

7.6.3.5. Taiwan

7.6.3.5.1. Market Trends and Opportunities

7.6.3.5.2. Growth Prospects

7.6.3.6. Thailand

7.6.3.6.1. Market Trends and Opportunities

7.6.3.6.2. Growth Prospects

7.6.3.7. Indonesia

7.6.3.7.1. Market Trends and Opportunities

7.6.3.7.2. Growth Prospects

7.6.3.8. Others

7.6.3.8.1. Market Trends and Opportunities

7.6.3.8.2. Growth Prospects

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

8.1. Major Players and Strategy Analysis

8.2. Market Share Analysis

8.3. Mergers, Acquisitions, Agreements, and Collaborations

8.4. Competitive Dashboard

9. COMPANY PROFILES

9.1. Cooper Surgical (Cook Medicals)

9.2. Vitrolife AB

9.3. Thermo Fisher Scientific Inc.

9.4. FUJIFILM Irvine Scientific

9.5. Nikon Instruments Inc.

9.6. Merck KGaA

9.7. Liverpool Partners (Genea Limited)

9.8. Hamilton Thorne, Inc. (IVFtech ApS)

Cooper Surgical (Cook Medicals)

Vitrolife AB

Thermo Fisher Scientific Inc.

FUJIFILM Irvine Scientific

Nikon Instruments Inc.

Merck KGaA

Liverpool Partners (Genea Limited)

Hamilton Thorne, Inc. (IVFtech ApS)